(P013) Perioperative Mortality in Nonelderly Adult Patients With Cancer: A Population-Based Study Evaluating Healthcare Disparities in the United States According to Insurance Status

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

In the largest reported analysis of perioperative mortality evaluating the 15 most common surgically treated malignancies, those with Medicaid coverage or without insurance were more likely to die within 30 days of surgery.

Arya Amini, Norman Yeh, Bernard Jones, Yevgeniy Vinogradskiy, Edward Bedrick, Chad G. Rusthoven, Ava Amini, William T. Purcell, Brian D. Kavanagh, Sana D. Karam, Christine M. Fisher; University of Colorado; Northwestern University

PURPOSE: Cancer survival is known to vary based on socioeconomic factors, including insurance status. The purpose of this study was to evaluate predictors for perioperative mortality (death within 30 d of cancer-directed surgery) for the 15 most common surgically treated cancers in the United States.

PATIENT AND METHODS: The Surveillance, Epidemiology, and End Results (SEER) database was examined for the 15 most common surgically resected cancers. The database was queried from 2007 to 2011, with a total of 506,722 patients included in the analysis. Binomial logistic regression was used to assess the effect of patient and tumor characteristics on perioperative mortality under multivariable analysis.

RESULTS: The insurance status for all patients was as follows: non-Medicaid insurance (83%), any Medicaid (10%), uninsured (4%), and unknown (3%). Under univariable analysis, predictors for perioperative mortality included Medicaid or uninsured status (P < .001), older age (≥ 60 yr) (P = .015), nonwhite race (P < .001), being unmarried (P < .001), urban and rural residence (vs metropolitan) (P = .002), higher percent of county below the federal poverty level (P < .001), and lower median household income (P < .001). Perioperative mortality was also associated with more advanced disease, including higher tumor stage (P < .001) and metastasis (P < .001). After adjusting for age, race, sex, marital status, residence (urban or rural), extent of disease (in situ, local, regional, distant), and percentage of county below federal poverty level, patients with either Medicaid insurance (odds ratio [OR] = 1.22; 95% confidence interval [CI], 1.15–1.29; P < .001) or uninsured status (OR = 1.75; 95% CI, 1.61–1.87; P < .001) were more likely to die within 30 days of surgery compared with patients with non-Medicaid insurance. Additional statistically significant predictors for perioperative mortality under multivariable analysis included rural residence (OR = 1.07), race-including being African-American (OR = 1.07), Hispanic, (OR = 1.27), and Asian or Pacific Islander (OR = 1.19)-and being unmarried (OR = 1.08).

CONCLUSION: In the largest reported analysis of perioperative mortality evaluating the 15 most common surgically treated malignancies, those with Medicaid coverage or without insurance were more likely to die within 30 days of surgery.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Related Content